AC6 Stock Overview
A pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
AlzeCure Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.074 |
| 52 Week High | SEK 0.31 |
| 52 Week Low | SEK 0.047 |
| Beta | 0.29 |
| 11 Month Change | -50.80% |
| 3 Month Change | -47.66% |
| 1 Year Change | -75.48% |
| 33 Year Change | -88.17% |
| 5 Year Change | -82.02% |
| Change since IPO | -91.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| AC6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -0.3% | 0.8% |
| 1Y | -75.5% | -18.3% | 8.6% |
Return vs Industry: AC6 underperformed the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: AC6 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| AC6 volatility | |
|---|---|
| AC6 Average Weekly Movement | 21.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AC6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AC6's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Martin Jönsson | www.alzecurepharma.se |
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications.
AlzeCure Pharma AB (publ) Fundamentals Summary
| AC6 fundamental statistics | |
|---|---|
| Market cap | €8.24m |
| Earnings (TTM) | -€3.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs AC6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AC6 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 35.66m |
| Earnings | -SEK 35.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AC6 perform over the long term?
See historical performance and comparison